SEC Company Response from Kiromic Biopharma, Inc. (KRBP) (CIK 0001792581) — Oct 13, 2020
Kiromic Biopharma, Inc. (KRBP) (CIK 0001792581)
Date: Oct. 13, 2020 · CIK: 0001792581 · Accession: 0001104659-20-114444
AI Filing Summary & Sentiment
File numbers found in text: 333-238153
Letter
Re: Kiromic BioPharma, Inc.
October 13, 2020
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-1,
File No. 333-238153
Acceleration Request
Requested Date: October 15, 2020
Requested Time: 5:00 p.m. Eastern Time (US)
Ladies and Gentlemen:
In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representative of the several underwriters, hereby join in the request of Kiromic BioPharma, Inc. that the effective date of the Registration Statement be accelerated so that it will be declared effective at 5:00 p.m., Eastern Time (US), on October 15, 2020, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Act, we wish to advise you that the underwriters have distributed as many copies of the preliminary prospectus to underwriters, dealers, institutions and others as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
THINKEQUITY
Show Raw Text
CORRESP
1
filename1.htm
October 13, 2020
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Kiromic BioPharma, Inc.
Registration
Statement on Form S-1,
File No. 333-238153
Acceleration Request
Requested Date: October 15, 2020
Requested Time: 5:00 p.m. Eastern Time (US)
Ladies and Gentlemen:
In connection with the above-referenced Registration
Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we, as representative
of the several underwriters, hereby join in the request of Kiromic BioPharma, Inc. that the effective date of the Registration
Statement be accelerated so that it will be declared effective at 5:00 p.m., Eastern Time (US), on October 15, 2020, or as soon
thereafter as practicable.
Pursuant to Rule 460 under the Act, we wish
to advise you that the underwriters have distributed as many copies of the preliminary prospectus to underwriters, dealers, institutions
and others as appears to be reasonable to secure adequate distribution of the preliminary prospectus.
The undersigned, as representatives of the several
underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied
and will comply, with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
Very truly yours,
THINKEQUITY
a division of Fordham Financial Management, Inc.
By:
/s/
Eric Lord
Name: Eric Lord
Title: Head of Investment Banking